Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-731-8180
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees117
Next Earnings Date10/22/2019 (Estimated)
OptionableNot Optionable
Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions
What is Odonate Therapeutics' stock symbol?
Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."
How were Odonate Therapeutics' earnings last quarter?
Odonate Therapeutics Inc (NASDAQ:ODT) announced its quarterly earnings results on Wednesday, July, 24th. The company reported ($1.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.24) by $0.09. View Odonate Therapeutics' Earnings History.
When is Odonate Therapeutics' next earnings date?
What is the consensus analysts' recommendation for Odonate Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Odonate Therapeutics.
Has Odonate Therapeutics been receiving favorable news coverage?
News coverage about ODT stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Odonate Therapeutics earned a news impact score of -1.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Odonate Therapeutics.
Are investors shorting Odonate Therapeutics?
Odonate Therapeutics saw a increase in short interest in August. As of August 15th, there was short interest totalling 1,324,200 shares, an increase of 12.7% from the July 15th total of 1,175,400 shares. Based on an average daily volume of 125,900 shares, the short-interest ratio is presently 10.5 days. Approximately 5.8% of the company's stock are short sold. View Odonate Therapeutics' Current Options Chain.
Who are some of Odonate Therapeutics' key competitors?
Some companies that are related to Odonate Therapeutics include FibroGen (FGEN), Evotec (EVTCY), Alkermes (ALKS), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), BridgeBio Pharma (BBIO), Reata Pharmaceuticals (RETA), Arrowhead Pharmaceuticals (ARWR), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Myokardia (MYOK), Genmab A/S (GMAB), Arena Pharmaceuticals (ARNA), Ultragenyx Pharmaceutical (RARE) and Biohaven Pharmaceutical (BHVN).
What other stocks do shareholders of Odonate Therapeutics own?
Who are Odonate Therapeutics' key executives?
Odonate Therapeutics' management team includes the folowing people:
- Mr. Kevin C. Tang, Chairman & CEO (Age 52)
- Mr. John G. Lemkey, Chief Operating Officer (Age 38)
- Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)
- Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
- Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43)
When did Odonate Therapeutics IPO?
(ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.
Who are Odonate Therapeutics' major shareholders?
Odonate Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Tang Capital Management LLC (43.73%), Boxer Capital LLC (10.45%), Janus Henderson Group PLC (4.09%), Janus Henderson Group PLC (4.09%), Price T Rowe Associates Inc. MD (3.24%) and Samsara BioCapital LLC (1.91%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Institutional Ownership Trends for Odonate Therapeutics.
Which major investors are selling Odonate Therapeutics stock?
ODT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Allianz Asset Management GmbH, JPMorgan Chase & Co., Rock Springs Capital Management LP, Jacobs Levy Equity Management Inc., Menta Capital LLC, Wells Fargo & Company MN and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Odonate Therapeutics.
Which major investors are buying Odonate Therapeutics stock?
ODT stock was purchased by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Price T Rowe Associates Inc. MD, Eagle Asset Management Inc., Carillon Tower Advisers Inc., Boxer Capital LLC, BlackRock Inc., Pictet Asset Management Ltd. and Pictet Asset Management Ltd.. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View Insider Buying and Selling for Odonate Therapeutics.
How do I buy shares of Odonate Therapeutics?
Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Odonate Therapeutics' stock price today?
One share of ODT stock can currently be purchased for approximately $28.57.
How big of a company is Odonate Therapeutics?
Odonate Therapeutics has a market capitalization of $919.67 million. The company earns $-88,960,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.View Additional Information About Odonate Therapeutics.
What is Odonate Therapeutics' official website?
How can I contact Odonate Therapeutics?
Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]
MarketBeat Community Rating for Odonate Therapeutics (NASDAQ ODT)
MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe ODT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days.
